{
    "id": "52880642",
    "text": "Glesatinib (MGCD265) is an experimental anti-cancer drug.glesatinib@cancer.gov It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer It is a spectrum selective tyrosine kinase inhibitor \"for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET\".Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs. Jan 2017 ==References== ==External links== *glesatinib@cancer.gov Category:Tyrosine kinase inhibitors Category:Acetamides Category:Thioureas Category:Fluoroarenes Category:Experimental cancer drugs ",
    "title": "Glesatinib"
}